FABP5 Inhibition against <i>PTEN</i>-Mutant Therapy Resistant Prostate Cancer

FABP5 Inhibition against <i>PTEN</i>-Mutant Therapy Resistant Prostate Cancer

Resistance to standard of care taxane and androgen deprivation therapy (ADT) causes the vast majority of prostate cancer (PC) deaths worldwide. We have developed RapidCaP, an autochthonous genetically engineered mouse model of PC. It is driven by the loss of PTEN and p53, the most common driver even...

Full description

Bibliographic Details
Main Authors: Manojit M. Swamynathan, Grinu Mathew, Andrei Aziz, Chris Gordon, Andrew Hillowe, Hehe Wang, Aashna Jhaveri, Jude Kendall, Hilary Cox, Michael Giarrizzo, Gissou Azabdaftari, Robert C. Rizzo, Sarah D. Diermeier, Iwao Ojima, Agnieszka B. Bialkowska, Martin Kaczocha, Lloyd C. Trotman
Format: Article
Language:English
Published: MDPI AG 2023-12-01
Series:Cancers
Subjects:
prostate cancer (PC)
PTEN tumor suppressor
lipid signaling
fatty acid binding proteins (FABPs)
FABP5
SBFI-103
Online Access:https://www.mdpi.com/2072-6694/16/1/60

Similar Items

Similar Items